Omega-3 fatty acids: Their neuroprotective and regenerative potential in traumatic neurological injury

Future Lipidology

Volumn 4, Issue 3, 2009, Pages 343-353

  Michael Titus, Adina T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Long chain omega 3 fatty acid; Neuroprotection; Neuroregeneration; Spinal cord injury; Traumatic brain injury

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; LINOLEIC ACID; NITRIC OXIDE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PIOGLITAZONE; PRESENILIN 1; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CEREBROSPINAL FLUID; DRUG MECHANISM; ENCEPHALITIS; EXCITOTOXICITY; GLIA CELL; HUMAN; LIPID PEROXIDATION; MORBIDITY; MORTALITY; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE CELL NECROSIS; NERVE FIBER REGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; QUALITY OF LIFE; REGENERATIVE ABILITY; REVIEW; SPINAL CORD INJURY; SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN INJURY; VASOSPASM;

RATTUS;

EID: 67249145092     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.19     Document Type: Review

References (92)

1. Brenna JT: Efficiency of conversion of α-linolenic acid to long chain n-3 fatty acids in man. Curr. Opin. Clin. Nutr. Metab. Care 5, 127-132 (2002).
2. Burdge GC: Metabolism of α-linolenic acid in humans. Prostaglandins Leukot. Essent. Fatty Acids 75, 161-168 (2006).
3. Simopoulos AP: Evolutionary aspects of diet, the omega-3:omega-6 ratio and genetic variation: nutritional implications for genetic diseases. Biomed. Pharmacother. 60, 2-7 (2006).
4. Simopoulos AP: The importance of the omega-6:omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp. Biol. Med. 233, 674-688 (2008).
5. McNamara RK, Carlson SE: Role of omega-3 fatty acids on brain development and function. Prostaglandins Leukot. Essent. Fatty Acids 75, 329-349 (2006).
6. Lin YH, Salem N Jr: Whole body distribution of deuterated linoleic and α-linolenic acids and their metabolites in the rat. J. Lipid Res. 48, 2709-2724 (2007).
7. Brenna JT, Diau GY: The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. Prostaglandins Leukot. Essent. Fatty Acids 77, 247-250 (2007).
8. Horrocks LA, Farooqui AA: Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot. Essent. Fatty Acids 70, 361-372 (2004).
9. Calder PC: Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients. Braz. J. Med. Biol. Res. 36, 433-446 (2003).
10. Calder PC: n-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 38, 343-352 (2003).
11. Niu SL, Mitchell DC, Lim S-Y et al.: Reduced G protein-coupled signaling efficiency in retinal rod outer segments in response to n-3 fatty acid deficiency. J. Biol. Chem. 279, 31098-31104 (2004).
12. Li Q, Wang M, Tan L et al.: Docosahexaenoic acid changes lipid composition and interleukin-2 receptor signaling in membrane rafts. J. Lipid Res. 46, 1904-1913 (2005).
13. Martinez M, Vazquez E, Garcia-Silva MT: Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders. Am. J. Clin. Nutr. 71, 376-385 (2000).
14. Calon F, Cole G: Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot. Essent. Fatty Acids 77, 287-293 (2007).
15. Ross BM, Sequin J, Sieswerda LE: Omega-3 fatty acids as treatment for mental illness. Lipids Health Dis. 6, 21 (2008).
16. Puri BK, Bydder GM, Manku MS et al.: Reduction in cerebral atrophy associated with ethyl-eicosapentanoic acid treatment in patients with Huntington's disease. J. Int. Med. Res. 36, 896-905 (2008).
17. Dyall SC, Michael-Titus AT: Neurological benefits of omega-3 fatty acids. Neuromolecular Med. 10(4), 219-235 (2008).
18. Hawryluk GWJ, Rowland J, Kwon BK, Fehlings MG: Protection and repair of the injured spinal cord: a review of completed, ongoing and planned clinical trials for acute spinal cord injury. Neurosurg. Focus 25, 1-16 (2008).
19. Profyris C, Cheema SS, Zang DW et al. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol. Dis. 15, 415-436 (2004).
20. Li GL, Brodin G, Farooque M et al.: Apoptosis and expression of Bcl-2 after compression trauma to rat spinal cord. J. Neuropathol. Exp. Neurol. 55, 280-289 (1996).
21. Xu GY, Hughes MG, Ye Z, Hulsebosch CE, McAdoo DJ: Concentrations of glutamate released following spinal cord injury kill oligodendrocytes in the spinal cord. Exp. Neurol. 187, 329-336 (2004).
22. Gomes-Leal W, Corkill DJ, Freire MA, Picanco-Diniz CW, Perry VH: Astrocytosis, microglia activation, oligodendrocyte degeneration, and pyknosis following acute spinal cord injury. Exp. Neurol. 190, 456-467 (2004).
23. Conti A, Cardali S, Genovese T et al.: Role of inflammation in the secondary injury following experimental spinal cord trauma. J. Neurosurg. Sci. 47, 89-94 (2003).
24. Xiong Y, Rabchevsky AG, Hall ED: Role of peroxynutrite in secondary oxidative damage after spinal cord injury. J. Neurochem. 100, 639-649 (2006).
25. Baptiste DC, Fehlings MG: Pharmacological approaches to repair the injured spinal Cord. J. Neurotrauma 23, 318-334 (2006).
26. Farooqui AA, Ong WY, Horrocks LA: Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol. Rev. 58, 591-620 (2006).
27. Fleming JC, Norenberg AD, Ramsay DA et al.: The cellular inflammatory response in human spinal cords after injury. Brain 129, 3249-3269 (2006).
28. Gris D, Hamilton EF, Weaver LC: The systemic inflammatory response after spinal cord injury damages lungs and kidneys. Exp. Neurol. 211, 259-270 (2008).
29. Gibson AE, Bucholz AC, Martin Ginis KA et al.: C-reactive protein in adults with chronic spinal cord injury; increased chronic inflammation in tetraplegia vs. paraplegia. Spinal Cord 46, 616-621 (2008).
30. Schwartz M: Macrophages and microglia in central nervous system injury: are they helpful or harmful? J. Cereb. Blood Flow Metab. 23, 385-394 (2003).
31. Blesch A, Tuszynski M: Spinal cord injury: plasticity, regeneration and the challenge of translational drug development. Trends Neurosci. 32(1), 41-47 (2009).
32. Sahuquillo J, Poca MA, Amoros S: Current aspects of pathosphysiology and cell dysfunction after severe head injury. Curr. Pharm. Design 7, 1475-1503 (2001).
33. Werner C, Engelhard K: Pathophysiology of traumatic brain injury. Brit. J. Anaesthes. 99, 4-9 (2007).
34. Raghuphati R, Graham DI, McIntosh TK: Apoptosis after traumatic brain injury. J. Neurotraumai 17, 927-938 (2000).
35. Lenzlinger PM, Morganti-Kossmann MC, Laurer HL et al.: The duality of the inflammatory response to traumatic brain injury. Mol. Neurobiol. 24, 169-181 (2001).
36. Morganti-Kossmann MC, Rancan M, Stahel PF et al.: Inflammatory response in traumatic brain injury: a double-edged sword. Curr. Opin. Crit. Care 8, 101-105 (2002).
37. Pilitsis JG, Coplin WM, O'Regan MH et al.: Free fatty acids in cerebrospinal fluids from patients with traumatic brain injury. Neurosci. Lett. 349, 136-138 (2003).
38. Raghupathi R, Strauss KI, Zhang C et al.: Temporal alterations in cellular Bax:Bcl-2 ratio following traumatic brain injury in the rat. J. Neurotrauma 20, 421-435 (2003).
39. Uryu K, Chen XH, Martinez D et al.: Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp. Neurol. 208, 185-192 (2007).
40. Wang KK, Larner SF, Robinson G, Hayes RL: Neuroprotection targets after traumatic brain injury. Curr. Opin. Neurol. 19, 514-519 (2006).
41. Schouten JW: Neuroprotection in traumatic brain injury: a complex struggle against the biology of nature. Curr. Opin. Crit. Care 13, 134-142 (2007).
42. Lang-Lazdunski L, Blondeau N, Jarretou G et al.: Linolenic acid prevents neuronal cell death and paraplegia after transient spinal cord ischemia in rats. J. Vasc. Surg. 38, 564-575 (2003).
43. Lauritzen I, Blondeau N, Heurteaux C et al.: Polyunsaturated fatty acids are potent neuroprotectors. EMBO J. 19, 1784-1793 (2000).
44. Blondeau N, Widmann N, Lazdunski M, Heurteaux C: Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience 109, 231-241 (2002).
45. Mori TA, Beilin LJ: Omega-3 fatty acids and inflammation. Curr. Atheroscler. Rep. 6, 461-467 (2004).
46. Wang X, Zhao X, Mao ZY, Wang XM, Liu ZL: Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures, Neuroreport 14, 2457-2461 (2003).
47. King VR, Huang WL, Dyall SC et al.: Omega-3 fatty acids improve recovery, whereas omega-6 fatty acids worsen outcome, after spinal cord injury in the adult rat. J. Neurosci. 26, 4672-4680 (2006).
48. Huang WL, King VR, Curran OE et al.: A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain 130, 3004-3019 (2007).
49. Lim SN, Huang WL, Ward RE et al.: The acute administration of eicosapentaenoic acid is neuroprotective after spinal cord compression injury in rats. Presented at: Society of Neuroscience Meeting. (Abstract 651.11), Washington, DC, USA 15-19 November 2008.
50. Wu A, Ying Z, Gomez-Pinilla F: Omega-3 fatty acids normalize BDNF levels, reduce oxidative damage and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma 21, 1457-1467 (2004).
51. Wu A, Molteni R, Ying Z, Gomez-Pinilla F: A saturated fat diet aggravates the outcome of traumatic brain injury on hippocampal plasticity and cognitive function by reducing brain-derived neurotrophic factor. Neuroscience 119, 365-375 (2003).
52. Wu A, Ying Z, Gomez-Pinilla F: Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J. Neurotrauma 24, 1587-1595 (2007).
53. Yoneda H, Shirao S, Kurokawa T et al.: Does eicosapentaenoic acid (EPA) inhibit cerebral vasospasm in patients after aneurysmal subarachnoid haemorrhage? Acta Neurol. Scand. 118, 54-59 (2008).
54. Vreugdenhil M, Bruehl C, Voskuyl RA et al.: Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc. Natl Acad. Sci. USA 93, 12559-12563 (1996).
55. Boland LM, Drzewiecki MM: Polyunsaturated fatty acid modulation of voltage-gated ion channels. Cell Biochem. Biophys. 52, 59084 (2008).
56. Mata de Urquiza A, Liu S, Sjoberg M et al.: Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290, 2140-2144 (2000).
57. Schrage K, Koopmans G, Joosten EA, Mey J: Macrophages and neurons are targets of retinoic acid signaling after spinal cord contusion injury. Eur. J. Neurosci. 23, 285-295 (2006).
58. Michalik L, Wahli W: Involvement of PPAR nuclear receptors in tissue injury and wound repair. J. Clin. Invest. 116, 598-606 (2006).
59. McTigue DM, Tripathi R, Wei P, Lash AT: The PPAR γ agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp. Neurol. 205, 396-406 (2007).
60. Park SW, Yi JH, Miranpuri G et al.: Thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J. Pharmacol. Exp. Ther. 320, 1002-1012 (2007).
61. Tureyen K, Kapadia R, Bowen KK et al.: Peroxisome proliferator-activated receptor-γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and Type-2 diabetic rodents. J. Neurochem. 101, 41-56 (2007).
62. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R: PPARγ agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 1244, 164-172 (2008).
63. Akbar M, Calderon F, Wen Z et al.: Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc. Natl Acad. Sci. USA 102, 10858-10863 (2005).
64. Kim H-Y: Novel metabolism of docosahexaenoic acid in neural cells. J. Biol Chem. 282, 18661-18665 (2007).
65. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN: Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278, 14677-14687 (2003).
66. Serhan CN, Arita M, Hong S, Gotlinger K: Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 39, 1125-1132 (2004).
67. Marcheselli VL, Hong S, Lukiw WJ et al.: Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 273, 43807-43817 (2003).
68. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG: Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl Acad. Sci. USA 101, 8491-8496 (2004).
69. Bazan NG: Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci. 29, 263-271 (2006).
70. Calderon F, Kim H-Y: Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J. Neurochem. 90, 979-988 (2004).
71. Cao D, Xue R, Xu J, Liu Z: Effects of docosahexaenoic acid on the survival and neurite outgrowth of rat cortical neurons in primary cultures. J. Nutr. Biochem. 16, 538-546 (2005).
72. Robson LG, Dyall SC, Sidloff D, Michael-Titus AT: Omega-3 fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals. Neurobiol. Aging DOI: 10.1016/ j.neurobiolaging.2008.05.027. (2008) (Epub ahead of print).
73. Moran LB, Graeber MB: The facial nerve axotomy model. Brain Res. Brain Res. Rev. 44, 154-178 (2004).
74. Cao DH, Xu JF, Xue RH, Zheng WF, Liu ZL: Protective effect of chronic ethyl docosahexaenoate administration on brain injury in ischemic gerbils. Pharmacol. Biochem. Behav. 79, 651-659 (2004).
75. Belayev L, Marcheselli VL, Khoutorova L et al.: Docosahexaenoic acid complexed to albumin elicits high-grade ischaemic neuroprotection. Stroke 36, 118-123 (2005).
76. Heller AR, Rössler S, Litz RJ et al.: Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit. Care Med. 34, 972-979 (2006).
77. Peterson LD, Jeffery NM, Thies F et al.: Eicosapentaenoic and docosahexaenoic acid alter rat spleen leukocyte fatty acid composition and prostaglandin E2 production but have different effects on lymphocyte functions and cell-mediated immunity. Lipids 33, 171-180 (1998).
78. Cansev M, Wurtman RJ, Sakamoto T, Ulus IH: Oral administration for circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses. Alzheimers Dement. 4(1 Suppl. 1), 153-168 (2008).
79. Holguin S, Martinez J, Chow C, Wurtman R: Dietary uridine enhances the improvement in learning and memory produced by administering DHA in gerbils. FASEB J. 22, 3938-3946 (2008).
80. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al.: ε-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study. Arch. Neurol. 63, 1402-1408 (2006).
81. Wu A, Ying Z, Gomez-Pinilla F: Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience 155, 751-759 (2008).
82. Browne K, Iwata A, Putt M et al.: Chronic ibuprofen administration worsens cognitive outcome following traumatic brain injury in rats. Exp. Neurol. 201, 301-307 (2006).
83. Huang PL, Zandi PP, Tucker KL et al.: Benefits of fatty fish on dementia risk are stronger for those without APOE ε4. Neurology 65, 1409-1414 (2005).
84. Hibbeln JR, Nieminen LRG, Blasbalg TL et al.: Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am. J. Clin. Nutr. 83, 1483-1493 (2006).
85. Falo MC, Fillmore HL, Reeves TM et al.: Matrix metalloproteinase-3 expression profile differentiates adaptive and maladaptive synaptic plasticity induced by traumatic brain injury. J. Neurosci. Res. 84, 764-781 (2006).
86. Rabchevski AG: Segmental organization of spinal reflexes mediating autonomic dysreflexia after spinal cord injury. Prog. Brain Res. 152, 265-274 (2006).
87. Weaver LC, Marsh DR, Gris D, Brown A, Dekaban GA: Autonomic dysreflexia after spinal cord injury: central mechanisms and strategies for prevention. Prog. Brain Res. 152, 245-263 (2006)
88. Hou S, Duale H, Cameron AA et al.: Plasticity of lumbosacral propriospinal neurons is associated with the development of autonomic dysreflexia after thoracic spinal cord transaction. J. Comp. Neurol. 9, 382-399 (2008).
89. Pérez J, Ware MA, Chevalier S et al.: Dietary omega-3 fatty acids may be associated with increased neuropathic pain in nerve-injured rats. Anesth. Analg. 101, 444-448 (2005).
90. Itoh T, Yamamoto K: Peroxisome proliferator activated receptor γ and oxidized docosahexaenoic acids as new class of ligand. Naunyn-Schmiedeberg's Arch. Pharmacol. 377, 541-547 (2008).
91. Saatman KE, Duhaime AC, Bullock R et al.: Classification of traumatic brain injury for targeted therapies. J. Neurotrauma 25, 719-738 (2008).
92. Clarke J, Herberg G Peeling J, Buist R, Corbett D: Dietary supplementation of omega-3 polyunsaturated fatty acids worsens forelimb motor function after intracerebral hemorrhage in rats. Exp. Neurol. 191, 119-127 (2005).